Press Release
Full Year 2007 results date notification – 21 February 2008
12 Feb 2008 - Basingstoke, UK and Philadelphia, US – 12 February 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, will announce full year 2007 earnings on Thursday 21 February 2008.
Results press release will be issued at: 12:00 GMT / 07:00 EST
Investor meeting and conference call time: 14:00 GMT / 09:00 EST
Investor & Analyst meeting and conference call:
Matthew Emmens, Chief Executive Officer, Angus Russell, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:00 GMT/9:00 EST.
The meeting will take place at the offices of Deutsche Bank, Winchester House, 1 Great Winchester Street, London, EC2N 2DB.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
